✉ Email this page to a colleague
« Back to Dashboard
Doryx is a drug marketed by Mayne Pharma Intl, Warner Chilcott, and Mayne Pharma. and is included in three NDAs. There are five patents protecting this drug.
This drug has two patent family members in two countries.
The generic ingredient in DORYX is doxycycline hyclate. There are twenty-eight drug master file entries for this compound. Sixty-eight suppliers are listed for this compound. Additional details are available on the doxycycline hyclate profile page.
A generic version of DORYX was approved as doxycycline hyclate by CARIBE HOLDINGS on November 8th, 1982.
Summary for DORYX
|Finished Product Suppliers / Packagers:||2|
|Raw Ingredient (Bulk) Api Vendors:||51|
|Formulation / Manufacturing:||see details|
|Drug Prices:||Drug price information for DORYX|
|Patent Litigation and PTAB cases:||See patent lawsuits and PTAB cases for DORYX|
|What excipients (inactive ingredients) are in DORYX?||DORYX excipients list|
|DailyMed Link:||DORYX at DailyMed|
Anatomical Therapeutic Chemical (ATC) Classes for DORYX
DORYX is protected by two US patents.
Patents protecting DORYX
Modified release coated drug preparation
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TO TREAT OR PREVENT INFECTIONS CAUSED BY SUSCEPTIBLE BACTERIA USING DELAYED-RELEASE TABLETS CONSISTING OF DOXYCYCLINE HYCLATE COATED PELLETS IN A TABLET
See the table below for patents covering DORYX around the world.
|Country||Patent Number||Title||Estimated Expiration|
|Australia||2005299253||Improved tabletting process||See Plans and Pricing|
|World Intellectual Property Organization (WIPO)||2006045152||See Plans and Pricing|
|>Country||>Patent Number||>Title||>Estimated Expiration|